238 related articles for article (PubMed ID: 17867525)
21. Optimization of matrix tablets controlled drug release using Elman dynamic neural networks and decision trees.
Petrović J; Ibrić S; Betz G; Đurić Z
Int J Pharm; 2012 May; 428(1-2):57-67. PubMed ID: 22402474
[TBL] [Abstract][Full Text] [Related]
22. Sustained release phenylpropanolamine hydrochloride from ATO 888 matrix.
Perez MA; Ghaly ES; Marti A
P R Health Sci J; 1993 Dec; 12(4):263-7. PubMed ID: 8140204
[TBL] [Abstract][Full Text] [Related]
23. Zero-order release of theophylline from a core-in-cup tablet in sequenced simulated gastric and intestinal fluid.
Danckwerts MP; van der Watt JG; Moodley I
Drug Dev Ind Pharm; 1998 Feb; 24(2):163-7. PubMed ID: 15605446
[TBL] [Abstract][Full Text] [Related]
24. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of hydrophobic materials as matrices for controlled-release drug delivery.
Quadir MA; Rahman MS; Karim MZ; Akter S; Awkat MT; Reza MS
Pak J Pharm Sci; 2003 Jul; 16(2):17-28. PubMed ID: 16414573
[TBL] [Abstract][Full Text] [Related]
26. Estimation of the percolation thresholds in acyclovir hydrophilic matrix tablets.
Fuertes I; Miranda A; Millán M; Caraballo I
Eur J Pharm Biopharm; 2006 Nov; 64(3):336-42. PubMed ID: 16876392
[TBL] [Abstract][Full Text] [Related]
27. Controlled-release carbamazepine granules and tablets comprising lipophilic and hydrophilic matrix components.
Barakat NS; Elbagory IM; Almurshedi AS
AAPS PharmSciTech; 2008; 9(4):1054-62. PubMed ID: 18843537
[TBL] [Abstract][Full Text] [Related]
28. Effect of binders on the release rates of direct molded verapamil tablets using twin-screw extruder in melt granulation.
Tan DC; Chin WW; Tan EH; Hong S; Gu W; Gokhale R
Int J Pharm; 2014 Mar; 463(1):89-97. PubMed ID: 24406670
[TBL] [Abstract][Full Text] [Related]
29. Scleroglucan sustained-release oral preparations. Part I. In vitro experiments.
Touitou E; Alhaique F; Riccieri FM; Riccioni G; Santucci E
Drug Des Deliv; 1989 Dec; 5(2):141-8. PubMed ID: 2577984
[TBL] [Abstract][Full Text] [Related]
30. Time-controlled pulse-drug release from dry-coated wax matrix tablets for colon drug delivery.
Peerapattana J; Otsuka K; Otsuka M
Biomed Mater Eng; 2004; 14(3):293-301. PubMed ID: 15299241
[TBL] [Abstract][Full Text] [Related]
31. The manufacture and characterisation of hot-melt extruded enteric tablets.
Andrews GP; Jones DS; Diak OA; McCoy CP; Watts AB; McGinity JW
Eur J Pharm Biopharm; 2008 May; 69(1):264-73. PubMed ID: 18164604
[TBL] [Abstract][Full Text] [Related]
32. Formulation of sustained - release lithium carbonate matrix tablets: influence of hydrophilic materials on the release rate and in vitro-in vivo evaluation.
Emami J; Tavakoli N; Movahedian A
J Pharm Pharm Sci; 2004 Nov; 7(3):338-44. PubMed ID: 15576014
[TBL] [Abstract][Full Text] [Related]
33. Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum.
Fukuda M; Peppas NA; McGinity JW
Int J Pharm; 2006 Mar; 310(1-2):90-100. PubMed ID: 16413153
[TBL] [Abstract][Full Text] [Related]
34. A comparative study between melt granulation/compression and hot melt extrusion/injection molding for the manufacturing of oral sustained release thermoplastic polyurethane matrices.
Verstraete G; Mertens P; Grymonpré W; Van Bockstal PJ; De Beer T; Boone MN; Van Hoorebeke L; Remon JP; Vervaet C
Int J Pharm; 2016 Nov; 513(1-2):602-611. PubMed ID: 27686052
[TBL] [Abstract][Full Text] [Related]
35. High-amylose sodium carboxymethyl starch matrices for oral, sustained drug-release: formulation aspects and in vitro drug-release evaluation.
Brouillet F; Bataille B; Cartilier L
Int J Pharm; 2008 May; 356(1-2):52-60. PubMed ID: 18280069
[TBL] [Abstract][Full Text] [Related]
36. An investigation into effects of in vitro test condition on the release properties of theophylline from HPMC matrices using factorial design.
Petrovic A; Ibric S; Trajkovic S; Popovic R; Djuric Z; Popadic D
Arch Pharm Res; 2009 Jul; 32(7):1087-96. PubMed ID: 19641891
[TBL] [Abstract][Full Text] [Related]
37. Photoimages and the release characteristics of lipophilic matrix tablets containing highly water-soluble potassium citrate with high drug loadings.
Cao QR; Kim TW; Lee BJ
Int J Pharm; 2007 Jul; 339(1-2):19-24. PubMed ID: 17532156
[TBL] [Abstract][Full Text] [Related]
38. Surelease as granulating liquid in preparation of sustained release matrices of ethylcellulose and theophylline.
Afrasiabi Garekani H; Faghihnia Torshizi M; Sadeghi F
Drug Dev Ind Pharm; 2015; 41(10):1655-60. PubMed ID: 25402967
[TBL] [Abstract][Full Text] [Related]
39. Melt granulation and heat treatment for wax matrix-controlled drug release.
Zhang YE; Schwartz JB
Drug Dev Ind Pharm; 2003 Feb; 29(2):131-8. PubMed ID: 12648009
[TBL] [Abstract][Full Text] [Related]
40. [On the manufacture and testing of butaperazine matrix tablets with silicone varnish NH 30 as a structural substance (author's transl)].
Kala H; Wendorff D; Moldenhauer H
Pharmazie; 1980; 35(7):418-23. PubMed ID: 6106210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
